Clear.bio

Founded in 2019 by Piet Hein van Dam and Madelon Bracke, Clear.bio is an Amsterdam-based health technology company providing real-time nutritional advice and continuous blood glucose monitoring for individuals with type 2 diabetes. The subscription-based platform integrates a chip-implanted arm patch, an artificial intelligence-powered mobile application, and digital coaching to deliver precision nutrition recommendations aimed at managing blood sugar levels without medication. Operating with approximately ten professionals, the organization has raised 1,700,000 euros in funding and serves thousands of active users, historically adding around 150 new patients monthly. The enterprise secured a CE mark as a Class I medical device and established strategic partnerships with major health insurer Zilveren Kruis and the Diabetes Vereniging Nederland. In addition to winning the VBHC Dragons Grant, the official healthcare provider recently expanded into the Brazilian market and achieved multiple ISO certifications.

Clear.bio is a Dutch health‑tech company that builds a data‑driven, personalized nutrition and coaching program—centered on continuous glucose monitoring, an AI food recommender, and human dietitian support—to help people with type 2 diabetes improve glycemic control and reduce reliance on medication[2][4].[1]

High‑Level Overview

• Clear.bio’s mission is to “make better health simple and accessible” and to help people with type 2 diabetes become healthier using modern technology and the latest nutritional science rather than immediate medication[1][3].[5]
  - Product and customers: Clear.bio offers a digital health program that combines a personal glucose sensor (glucometry), a mobile app with proprietary glucose‑analysis algorithms and an AI food recommender, plus access to dietitians/coaches; its primary customers are people with type 2 diabetes and healthcare partners (insurers and providers) who run pilots and reimburse services[4][6][5].
  - Problem solved: The service reveals individual blood‑glucose responses to foods in real time and delivers personalized dietary advice so users can stabilize blood sugar, lose weight, and in many cases improve or reverse poor glycemic control[2][4][5].
  - Growth momentum: Founded in 2019, Clear.bio has run pilots with Dutch insurers and healthcare partners, raised multiple rounds (reported €1.1M and later another €1M, total funding noted ~€3.7M in reporting), and aims for prescription/reimbursement and geographic pilots beyond the Netherlands (Brazil, Portugal noted in reporting)[2][4][6][5].

Origin Story

• Founders and founding year: Clear.bio was founded in 2019 by Piet Hein van Dam (PhD, CEO) and Madelon Bracke (PhD, CSO) as a health‑tech spin‑out; the founders combine scientific and industry/entrepreneurial backgrounds[2][3][4].
  - How the idea emerged: The company originated from the insight that individual biological reactions to food vary and that real‑time glucose data can be used to personalize nutrition and change behavior—Piet Hein and Madelon translated bioscience and personal glucose monitoring into an app + coaching service[4][2].
  - Early traction and pivotal moments: Early pilots with insurers and Diabetesvereniging Nederland produced promising results (many participants improved or halted disease progression within months), Clear.bio joined innovation lists and won recognition for its approach, and it secured investor support from Healthy.Capital and Achmea’s Innovation Fund while raising successive seed rounds[5][4][8].

Core Differentiators

• Personalization via real‑time biodata: Uses personal glucose monitoring as the core signal to detect individual responses to specific foods and generate 100% personalized advice[4][2].
  - Integrated tech + human coaching: Combines an AI food recommender and proprietary glucose‑analysis algorithms with on‑demand dietitians/coaches in the app for behavioral support[4][6].
  - Healthcare integration and reimbursement focus: Actively piloting with insurers and healthcare providers to become a prescribed/reimbursable treatment in the Netherlands, which can drive scale and clinical adoption[5][2].
  - Measured short‑term clinical impact: Company reports substantial early outcome metrics (example: ~70% of poorly regulated T2D users lowering eHbA1c by 11.6 mmol/mol [−1.1%] in 3 months per company reporting), suggesting faster/cheaper effects vs alternatives (reported by Clear.bio in interviews)[3].
  - Science‑led team: Founders and key staff include PhDs in bioscience and former industry scientists, emphasizing evidence and clinical validation in product design[1][3].

Role in the Broader Tech Landscape

• Trend alignment: Clear.bio rides the convergence of wearable/continuous biomonitoring, AI personalization, and digital therapeutics focused on behavior change for chronic metabolic disease[2][4].
  - Why timing matters: Rising prevalence and cost of type 2 diabetes, increased payer interest in scalable preventive digital care, and wider acceptance of remote monitoring create favorable market conditions for data‑driven dietetics[5][4].
  - Market forces in their favor: Insurer pilots and investment from healthcare funds indicate demand for solutions that reduce long‑term treatment costs and improve patient self‑management[5][4].
  - Ecosystem influence: By demonstrating reimbursement pathways and clinical impact with real‑world pilots, Clear.bio could accelerate adoption of personalized nutrition as a reimbursable component of chronic‑disease management and push other digital‑therapeutic vendors to integrate biosensing + coaching models[5][2][4].

Quick Take & Future Outlook

• Near‑term priorities: Securing formal reimbursement/prescription status in the Netherlands, scaling through insurer and provider partnerships, and expanding pilots internationally (Brazil and Portugal pilots were reported as planned)[2][5].
  - Key risks and enablers: Clinical validation and durable outcomes will determine payer adoption; regulatory/medical classification and data security are additional considerations, while strong pilot results and insurer buy‑in are critical enablers[5][4].
  - How influence may evolve: If Clear.bio converts pilot results into reimbursed standard care and demonstrates sustained reductions in medication use and healthcare utilization, it could become a leading European digital therapeutic for T2D and a model for precision nutrition services globally[5][3][2].
  - Final note: Clear.bio’s combination of continuous glucose data, AI personalization and human coaching targets a tangible, high‑value problem (type 2 diabetes management) at a time when payers and patients are receptive—execution on clinical validation and reimbursement will determine whether it becomes a broad, scalable alternative to medication‑first pathways[4][5][2].